Protalix BioTherapeutics, Inc. (PLX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Protalix BioTherapeutics, Inc. (PLX) Healthcare & Pipeline Overview

Protalix BioTherapeutics, Inc. leverages its ProCellEx platform to develop and commercialize recombinant therapeutic proteins, primarily targeting rare diseases. Its lead product, Elelyso, addresses Gaucher disease, while its pipeline focuses on Fabry disease, cystic fibrosis, gout, and NETs-related diseases, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for PLX?

Protalix BioTherapeutics presents an investment opportunity centered on its ProCellEx platform and pipeline of rare disease therapies. The company's established revenue stream from Elelyso provides a foundation for growth, while the potential approval and commercialization of PRX-102 for Fabry disease represents a significant catalyst. Positive clinical trial results and regulatory approvals could drive substantial value appreciation. However, investors may want to evaluate the risks associated with clinical development, regulatory hurdles, and competition in the rare disease market. The company's negative profit margin of -12.5% also warrants attention. Successful execution of its clinical programs and strategic partnerships are crucial for realizing the company's long-term potential. The current market capitalization is $0.19B as of 2026-05-04.

Based on FMP financials and quantitative analysis

PLX Key Highlights

Protalix's proprietary ProCellEx platform enables efficient production of complex recombinant proteins.

• Elelyso, the company's approved product for Gaucher disease, generates revenue in multiple international markets.
• PRX-102, a therapeutic protein candidate for Fabry disease, is in the last stage of clinical trials.
• The company has strategic partnerships with Pfizer and Chiesi Farmaceutici S.p.A.
• Protalix's pipeline includes product candidates targeting cystic fibrosis, gout, and NETs-related diseases.

Who Are PLX's Competitors?

PLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PLX's Key Strengths?

Proprietary ProCellEx platform for protein expression.

• Approved product (Elelyso) generating revenue.
• Pipeline focused on rare diseases with unmet needs.
• Strategic partnerships with Pfizer and Chiesi.

What Are PLX's Weaknesses?

Negative profit margin (-12.5%).

• Reliance on a limited number of products.
• High R&D expenses.
• Dependence on regulatory approvals.

What Could Drive PLX Stock Higher?

Potential regulatory approval of PRX-102 for Fabry disease.

• Continued commercialization and market penetration of Elelyso.
• Progress in clinical trials for PRX-110, PRX-115, and PRX-119.
• Expansion of strategic partnerships and collaborations.

What Are the Key Risks for PLX?

Financial-distress signal — its Altman Z-Score of 0.44 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Rich valuation — a P/E of 44.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Clinical trial failures for pipeline candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other therapies for rare diseases.
• Intellectual property challenges and patent disputes.
• Dependence on key partnerships for development and commercialization.

What Are the Growth Opportunities for PLX?

• The successful completion of clinical trials and subsequent regulatory approval could allow Protalix to capture a substantial share of this market. The timeline for this growth opportunity is dependent on the clinical trial results and regulatory review process, with potential approval expected within the next 1-2 years.
• Development and Commercialization of PRX-110 for Cystic Fibrosis: PRX-110, a recombinant form of human deoxyribonuclease I, targets cystic fibrosis, a genetic disorder affecting the lungs and other organs. The cystic fibrosis market is substantial, with ongoing research and development efforts focused on improving treatment options. Positive results from ongoing clinical trials could pave the way for regulatory approval and commercialization, potentially expanding Protalix's product portfolio and revenue streams within the next 3-5 years.
• Advancement of PRX-115 for the Treatment of Gout: Protalix is developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase, for the treatment of gout. The gout market is growing due to the increasing prevalence of the disease. Successful development and commercialization of PRX-115 could provide Protalix with a new revenue stream and strengthen its position in the biopharmaceutical market within the next 4-6 years.
• Exploration of PRX-119 for NETs-Related Diseases: PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate, targets NETs-related diseases. This represents a novel approach to treating these conditions. Further research and development are needed to assess the potential of PRX-119. If successful, it could open up a new market for Protalix and contribute to its long-term growth within the next 5-7 years.
• Geographic Expansion of Elelyso and Future Products: Protalix has the opportunity to expand the geographic reach of Elelyso and future products. Entering new markets, particularly in emerging economies, could drive revenue growth and increase the company's global presence. This expansion strategy would involve securing regulatory approvals in new countries and establishing distribution partnerships. The timeline for geographic expansion will vary depending on the specific market and regulatory requirements, with ongoing efforts expected to yield results over the next several years.

What Opportunities Does PLX Have?

• Approval and commercialization of PRX-102 for Fabry disease.
• Expansion into new geographic markets.
• Development of new therapies for other rare diseases.
• Potential for acquisitions or licensing agreements.

What Are PLX's Competitive Advantages?

• Proprietary ProCellEx plant cell-based protein expression system.
• Established market presence with Elelyso for Gaucher disease.
• Pipeline of product candidates targeting rare diseases with unmet medical needs.
• Strategic partnerships with established pharmaceutical companies.

What Does PLX Do?

Founded in 1993 and headquartered in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company's core technology is its proprietary ProCellEx plant cell-based protein expression system, which allows for the production of complex proteins in a cost-effective and scalable manner. Protalix's lead product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy approved for the treatment of Gaucher disease, a rare genetic disorder. Elelyso is marketed in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey, among other countries. Beyond Elelyso, Protalix is advancing a pipeline of product candidates targeting other rare diseases, including Fabry disease (PRX-102), cystic fibrosis (PRX-110), gout (PRX-115), and NETs-related diseases (PRX-119). These product candidates are in various stages of clinical development. Protalix has established strategic partnerships with companies such as Pfizer and Chiesi Farmaceutici S.p.A. to support the development and commercialization of its products. The company's commitment to innovation and its focus on addressing unmet medical needs in the rare disease space drive its growth strategy.

What Products and Services Does PLX Offer?

• Develop and commercialize recombinant therapeutic proteins.
• Utilize the ProCellEx plant cell-based protein expression system.
• Offer Elelyso for the treatment of Gaucher disease.
• Advance PRX-102 for the treatment of Fabry disease.
• Develop PRX-110 for the treatment of cystic fibrosis.
• Create PRX-115 for the treatment of gout.
• Research PRX-119 for the treatment of NETs-related diseases.

How Does PLX Make Money?

• Develop novel therapies for rare diseases using the ProCellEx platform.
• Generate revenue through the sale of Elelyso and potential future products.
• Establish partnerships with pharmaceutical companies for development and commercialization.

What Industry Does PLX Operate In?

Protalix BioTherapeutics operates in the biotechnology industry, which is characterized by high R&D spending, long development timelines, and significant regulatory oversight. The market for rare disease therapies is growing due to increased awareness, improved diagnostics, and regulatory incentives. Protalix competes with other biotechnology companies developing therapies for rare diseases, including enzyme replacement therapies and gene therapies. The company's ProCellEx platform provides a potential competitive advantage in terms of production cost and scalability. The biotechnology industry is subject to intense competition and patent challenges.

Who Are PLX's Key Customers?

• Patients with Gaucher disease.
• Patients with Fabry disease (potential).
• Healthcare providers and hospitals.
• Pharmaceutical distributors.

Wall Street analysts project Protalix BioTherapeutics, Inc. revenue of about $78.3M for fiscal 2026, with EPS near $0.20.

Protalix BioTherapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 221.6% above estimates on average.

Protalix BioTherapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.44 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Protalix BioTherapeutics, Inc. stands at 28.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 15.0%, showing how much profit it generates from its asset base. PLX trades at a trailing price-to-earnings ratio of 44.61, above the Healthcare sector average of ~23x. Its free cash flow yield is 7.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.3%, the inverse of the P/E and a quick read on earnings relative to price.

Protalix BioTherapeutics, Inc. (PLX) Valuation Context

Valued at $192M, PLX is classified as a micro-cap stock. Relative to its peer group, PLX's quantitative score of 48/100 is below the peer average of 75/100.

PLX Revenue & Earnings Trend

In Q2 2026, PLX generated $19.9M in top-line revenue, marking a sequential decrease of 41.0%. The company recorded net income of $3.8M, with diluted EPS of $0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, PLX averaged $0.06 in diluted EPS.

Company Profile

Protalix BioTherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hackensack, US. The company is led by CEO Dror Bashan. PLX has traded publicly since 1998.

PLX Financials

PLX Latest News

PLX Analyst Consensus

PLX MoonshotScore

Common Questions About PLX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources